<DOC>
	<DOCNO>NCT00996957</DOCNO>
	<brief_summary>For cancer cell grow , need nutrient supply blood vessel . The study drug , ACE-041 , design work block growth blood vessel prevent cancer cell grow . The purpose study establish safe dose level ACE-041 patient advance solid tumor relapsed/refractory multiple myeloma follow multiple dose administration . This study also evaluate ACE-041 effect tumor .</brief_summary>
	<brief_title>Study ACE-041 Patients With Advanced Solid Tumors Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Diagnosis metastatic unresectable advanced solid tumor ( solid tumor must measurable ) relapsed/refractory multiple myeloma disease progress despite available standard therapy standard therapy exists . Life expectancy least 12 week . Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 , 1 , 2 ( decline within 2 week prior study day 1 ) . Central nervous system ( CNS ) metastases . Chemotherapy anticancer therapy within 4 week prior study day 1 , and/or nitrosoureas within 6 week prior study day 1 . Lack recovery toxic effect previous chemotherapy , radiation therapy , biologic therapy , and/or experimental therapy exception alopecia . Radiation therapy within 4 week prior study day 1 . Clinically significant pulmonary , cardiovascular , endocrine , neurologic , gastrointestinal genitourinary disease unrelated underlying solid tumor multiple myeloma Significant cardiac risk ( e.g . history myocardial infarction , unstable angina , pulmonary hypertension , clinically significant arrhythmia , congestive heart failure within 1 year prior study day 1 ) . Diagnosis family history hereditary hemorrhagic telangiectasia . Major surgery within 6 week prior study day 1 . Parenteral antibiotic , lifethreatening active infection require parenteral antibiotic therapy within 1 month prior study day 1 . Therapeutic anticoagulation . Uncontrolled hypertension . Autoimmune hereditary hemolysis . Clinically significant gastrointestinal bleeding clinically significant active bleeding within 3 month prior study day 1 . Treatment another investigational drug device , approve therapy investigational use within 28 day prior study day 1 . Pregnancy lactation female patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>